Gee Siobhan, Taylor David
Pharmacy Department, South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Denmark Hill, London SE5 8AZ, UK.
Pharmacy department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK.
Ther Adv Psychopharmacol. 2020 Jul 16;10:2045125320940935. doi: 10.1177/2045125320940935. eCollection 2020.
Clozapine is associated with haematological side effects, including neutropaenia, which can signal impending life-threatening agranulocytosis. Patients with COVID-19 infection frequently experience lymphopaenia, but not neutropaenia. We present 13 patients established on clozapine who developed COVID-19 infection. There were no significant differences in total white cell or neutrophil counts between pre-COVID-19, intra-COVID-19 or post-COVID-19 periods. We therefore suggest that patients who develop COVID-19 should generally have their clozapine treatment continued. Patients taking clozapine who develop neutroapaenia during COVID-19 infection should be investigated and monitored as in normal practice, because changes in neutrophil counts cannot be assumed to be due to the viral infection.
氯氮平与血液学副作用有关，包括中性粒细胞减少，这可能预示着即将发生危及生命的粒细胞缺乏症。感染新型冠状病毒肺炎（COVID-19）的患者经常出现淋巴细胞减少，但不会出现中性粒细胞减少。我们报告了13例服用氯氮平且感染了COVID-19的患者。在感染COVID-19之前、感染期间或感染之后，白细胞总数或中性粒细胞计数均无显著差异。因此，我们建议，感染COVID-19的患者通常应继续服用氯氮平。在COVID-19感染期间出现中性粒细胞减少的服用氯氮平患者，应按常规进行检查和监测，因为不能认为中性粒细胞计数的变化是由病毒感染引起的。
